Imbruvica gets US nod for marginal zone lymphoma
Janssen and AbbVie’s Imbruvica has been cleared by regulators in the US to treat certain patients with marginal zone lymphoma (MZL), a rare form of non-Hodgkin’s lymphoma.
Read More
Tag: marginal zone lymphoma
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
